VERAXA Biotech (NASDAQ: VRXA) announced a collaboration with AI-driven bioinformatics company Ardigen S.A. to support development of its BiTAC(R) pipeline of T-cell engagers and future antibody-drug conjugates. The partnership will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity.
VERAXA said integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates. To view the full press release, visit https://ibn.fm/GLFg2.
The integration of AI into drug development is not new, but its application to bispecific T-cell engagers represents a significant step forward. The BiTAC platform is designed to engage two different targets simultaneously, which can enhance tumor killing while sparing healthy cells. However, identifying the optimal pair of targets has been a major challenge, often leading to toxicity or lack of efficacy. By leveraging Ardigen’s AI capabilities, VERAXA aims to analyze vast amounts of data to predict which combinations are most likely to succeed, potentially accelerating the path to clinical trials and reducing the high failure rates associated with oncology drug development.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs and other innovative formats. Powered by a suite of transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development and beyond. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology.
Ardigen S.A. is a bioinformatics company that applies AI to accelerate drug discovery and development. The collaboration with VERAXA underscores the growing trend of partnerships between biotech firms and AI specialists to tackle complex biological problems. For VERAXA, this partnership could be a key differentiator in a competitive landscape where many companies are developing bispecific antibodies. The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in this article involve risks and uncertainties as described in VERAXA's filings with the SEC, including its most recent Annual Report on Form 10-K and subsequent quarterly reports. Undue reliance should not be placed on these statements, and the company undertakes no duty to update them unless required by law. The original release is available at www.newmediawire.com.
